Consumers and recovery advocates urge regulation, not prohibition of kratom

A series of consumers, recovery advocates and industry representatives urged the committee not to ban kratom outright (S1558) and recommended a regulated framework that would restrict synthetic analogues while allowing the natural leaf and well-tested products to remain available. Jennifer Healy, a mother and former health-plan executive, cautioned that a ban could remove a harm-reduction tool that helps some people manage chronic pain or withdrawal. John Cleveland, representing a nonprofit advocacy group for plant-based harm reduction, asked the committee to favor regulation that sets milligram limits, lab testing and labeling, arguing that prohibition would drive a black market. Owners and operators of licensed kava/kratom cafes in New England described offering measured, tea-style preparations and local regulation (e.g., Nashua’s 21-plus approach) as alternatives to prohibition. Vendors and industry witnesses recommended a Massachusetts version of the Kratom Consumer Protection Act, similar to laws adopted in some other states, to require age limits, lab testing and product standards while banning synthetic analogues such as isolated 7‑OH variants when sold unsafely. Why it matters: Witnesses said a ban would criminalize otherwise law-abiding consumers and remove an accessible option for people managing pain and opioid withdrawal, while a regulated approach would reduce incidents linked to contaminated or adulterated products. Outcome: Committee members did not vote; proponents of regulation asked for a regulatory path that balances consumer safety with access.